celsion is a biopharmaceutical company dedicated to the research and development of innovative, targeted therapies that address unmet medical needs in oncology. with the recent acquisition of egen, inc., celsion has become a fully integrated company with an extensive, complementary, multi-phase clinical pipeline; platform technologies for the discovery of novel, nucleic acid-based immunotherapies and other anti-cancer dna/rna therapies; and expertise from bench to bedside.
Company profile
Ticker
IMNN
Exchange
Website
CEO
Michael Tardugno
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
CELSION CORP, Celsion CORP, CHEUNG LABORATORIES INC
SEC CIK
Corporate docs
Subsidiaries
CLSN Laboratories, Inc. • Celsion GmbH ...
IRS number
521256615
IMNN stock data
Latest filings (excl ownership)
10-Q
2023 Q3
Quarterly report
14 Nov 23
8-K
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
14 Nov 23
S-8
Registration of securities for employees
11 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
IMUNON Reports Second Quarter 2023 Financial Results and Provides Business Update
10 Aug 23
8-K
Departure of Directors or Certain Officers
15 Jun 23
8-K
Departure of Directors or Certain Officers
14 Jun 23
UPLOAD
Letter from SEC
26 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
IMUNON Reports First Quarter 2023 Financial Results and Provides Business Update
11 May 23
Transcripts
IMNN
Earnings call transcript
2023 Q3
14 Nov 23
IMNN
Earnings call transcript
2023 Q2
10 Aug 23
IMNN
Earnings call transcript
2023 Q1
11 May 23
IMNN
Earnings call transcript
2022 Q3
16 Nov 22
IMNN
Earnings call transcript
2022 Q2
15 Aug 22
IMNN
Earnings call transcript
2022 Q2
15 Aug 22
IMNN
Earnings call transcript
2022 Q1
16 May 22
IMNN
Earnings call transcript
2022 Q1
16 May 22
IMNN
Earnings call transcript
2021 Q4
31 Mar 22
IMNN
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
4
Donald P Braun
21 Mar 23
4
Pok Yu Augustine Chow
21 Mar 23
4
Frederick J. Fritz
21 Mar 23
4
Christine A Pellizzari
21 Mar 23
4
James E Dentzer
21 Mar 23
4
Stacy Lindborg
21 Mar 23
4
Michael H Tardugno
21 Mar 23
4
Khursheed Anwer
21 Mar 23
4
JEFFREY WAYNE CHURCH
21 Mar 23
4
Goff Corinne Le
21 Mar 23
Financial summary
| Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm | 12.88 mm |
| Cash burn (monthly) | (no burn) | 1.67 mm | 1.30 mm | 1.83 mm | 1.49 mm | 1.69 mm |
| Cash used (since last report) | n/a | 3.61 mm | 2.81 mm | 3.96 mm | 3.22 mm | 3.65 mm |
| Cash remaining | n/a | 9.27 mm | 10.07 mm | 8.93 mm | 9.66 mm | 9.23 mm |
| Runway (months of cash) | n/a | 5.5 | 7.7 | 4.9 | 6.5 | 5.5 |
Institutional ownership, Q2 2023
62.0% owned by funds/institutions
| 13F holders | Current |
|---|---|
| Total holders | 18 |
| Opened positions | 0 |
| Closed positions | 3 |
| Increased positions | 5 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 425.14 mm |
| Total shares | 5.83 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| FiveMore Fund | 2.75 mm | $3.77 mm |
| Lincoln Park Capital Fund | 1.58 mm | $1.65 mm |
| CVI Investments | 1.10 mm | $0.00 |
| Vanguard | 121.85 k | $157.18 mm |
| Renaissance Technologies | 74.01 k | $95.00 k |
| BLK Blackrock | 67.16 k | $86.63 mm |
| Citadel Advisors | 51.67 k | $66.66 mm |
| Geode Capital Management | 48.93 k | $63.12 mm |
| STT State Street | 14.30 k | $18.45 mm |
| Susquehanna International | 10.86 k | $14.01 mm |
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 17 Mar 23 | Church Jeffrey Wayne | Stock Option Common Stock | Grant | Acquire A | No | No | 1.32 | 40,000 | 52.80 k | 95,950 |
| 17 Mar 23 | Goff Corinne Le | Stock Option Common Stock | Grant | Acquire A | No | No | 1.32 | 90,000 | 118.80 k | 320,000 |
| 17 Mar 23 | Tardugno Michael H | Stock Option Common Stock | Grant | Acquire A | No | No | 1.32 | 25,000 | 33.00 k | 215,846 |
| 17 Mar 23 | Khursheed Anwer | Stock Option Common Stock | Grant | Acquire A | No | No | 1.32 | 40,000 | 52.80 k | 85,688 |
| 17 Mar 23 | James E Dentzer | Stock Option Common Stock | Grant | Acquire A | No | No | 1.32 | 2,000 | 2.64 k | 4,667 |
News
Earnings Scheduled For November 14, 2023
14 Nov 23
Imunon: Q3 Earnings Insights
14 Nov 23
Imunon Q3 EPS $(0.37) Beats $(0.66) Estimate
14 Nov 23
Imunon's Earnings Outlook
13 Nov 23
IMUNON Announces First Patient Enrolled In Phase 1/2 Clinical Trial Of IMNN-001 In Combination With bevacizumab In Advanced Ovarian Cancer
18 Oct 23
Press releases
IMUNON's VP of R&D to Present at the Vaccines Summit-2023
14 Nov 23
IMUNON Reports Third Quarter 2023 Financial Results and Provides a Business Update
14 Nov 23
IMUNON to Hold Third Quarter 2023 Financial Results and Business Update Conference Call on Tuesday, November 14, 2023
7 Nov 23
IMUNON's Chief Science Officer to Present at the 3rd International Vaccines Congress
23 Oct 23
IMUNON CEO Dr. Corinne Le Goff to Participate in a Panel Discussion on Pandemic Preparedness at the United Nations
19 Oct 23